Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Net Margin (2017 - 2025)

Historic Net Margin for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to 834.87%.

  • Protagonist Therapeutics' Net Margin fell 1244900.0% to 834.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 22.54%, marking a year-over-year decrease of 319200.0%. This contributed to the annual value of 63.34% for FY2024, which is 1949400.0% up from last year.
  • Latest data reveals that Protagonist Therapeutics reported Net Margin of 834.87% as of Q3 2025, which was down 1244900.0% from 627.46% recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Net Margin registered a high of 81.32% during Q1 2024, and its lowest value of 4551.0% during Q2 2022.
  • In the last 5 years, Protagonist Therapeutics' Net Margin had a median value of 387.75% in 2021 and averaged 660.29%.
  • In the last 5 years, Protagonist Therapeutics' Net Margin plummeted by -106540200bps in 2021 and then surged by 4007000bps in 2022.
  • Over the past 5 years, Protagonist Therapeutics' Net Margin (Quarter) stood at 431.16% in 2021, then surged by 93bps to 30.46% in 2022, then skyrocketed by 279bps to 54.67% in 2023, then surged by 46bps to 79.8% in 2024, then tumbled by -1146bps to 834.87% in 2025.
  • Its Net Margin stands at 834.87% for Q3 2025, versus 627.46% for Q2 2025 and 41.15% for Q1 2025.